Skip to main content
. 2020 Jan 6;2020(1):CD006282. doi: 10.1002/14651858.CD006282.pub5

ASIRI 2008.

Methods Randomised, placebo‐controlled, double‐blind trial
Participants People with SMA types II or III, aged 6–20 years.
Interventions Riluzole 50 mg/day orally or placebo
Duration of treatment: 24 months
Follow‐up: 24 months
Outcomes Motor function (MFM scale), spirometry (FVC), Measure of Functional Independence, adverse events and tolerance evaluation.
Notes Study completed (December 2011), but no results available.